American Shared Hospital Services reports Q2 2026 revenue of $8.4M, up 19% YoY, driven by direct patient services and international operations. Learn more about their growth strategy.
American Shared Hospital Services reported second quarter 2026 revenue of approximately $8.4 million, up 19% year-over-year and exceeding the $7.1 million consensus estimate. The increase reflects strong operational performance across its direct patient services and international operations, validating the company’s strategic shift from equipment leasing to a diversified radiation oncology platform.
Key Takeaways
- Total revenue reached approximately $8.4 million, a 19% increase from $7.1 million in Q2 2025.
- Direct patient services revenue surged approximately 40% to $4.9 million, driven by higher patient procedures in Rhode Island and international centers.
- Proton beam therapy revenue rose 22% to about $2.3 million, supported by increased treatment volumes and favorable reimbursement trends.
- Operating cash flow generated was approximately $4.4 million in the first six months of 2026, contributing to an 80% increase in cash reserves to $6.8 million.
- Adjusted EBITDA for Q2 was approximately $1.3 million, down from $1.7 million in the prior year, reflecting ongoing investments in direct patient services.
Revenue Growth Driven by Direct Patient Services
American Shared Hospital Services experienced a robust 19% revenue growth in Q2 2026, totaling approximately $8.4 million compared to $7.1 million in the same period last year. This growth was largely fueled by a 40% increase in direct patient services revenue, which reached approximately $4.9 million. The company noted that this surge stemmed from heightened patient procedures at its Rhode Island radiation oncology centers, alongside solid performances from facilities in Peru and Pueblo, Mexico.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $8.4M | +19% | - |
| Direct Patient Services | $4.9M | +40% | - |
| Proton Beam Therapy | $2.3M | +22% | - |
| Cash Position | $6.8M | +80% | - |
| Adjusted EBITDA | $1.3M | -24% | - |
The improved performance indicates that the company's strategy to transition from equipment leasing to a more diversified revenue stream is beginning to pay off. Ray Stokowiak, Executive Chairman, emphasized that increased patient volumes and operational enhancements remain key drivers of profitability.
Operating Cash Flow and Financial Flexibility Improve
The company’s operating activities generated approximately $4.4 million in cash during the first half of 2026, leading to an 80% rise in cash reserves to $6.8 million. This increase in liquidity is crucial as it allows the company to manage its debt obligations while investing in growth opportunities. The company also completed a $2 million subordinated financing from a newly formed entity associated with Stokowiak, enhancing its capital structure without deviating from its strategic priorities.
Alexis Wallace, Interim CFO, noted that while there were some legal and professional costs impacting net loss, the core operations remained resilient. The company is focused on leveraging its cash flow to address its balance sheet, which includes obligations of approximately $15.5 million to Fifth Third Bank.
International Operations Show Promising Trends
The company’s international operations are gaining traction, particularly in Latin America, where it has seen significant growth in patient volumes. Its Gamma Knife center in Peru, upgraded last year, has shown improved efficiency and throughput. Stokowiak highlighted that the partnership with Hospital San Xavier in Guadalajara, Mexico is an important step towards expanding their Gamma Knife services in a well-established market.
The Proton Beam Radiation Therapy in Orlando, Florida also reported a 22% revenue increase year-over-year, reflecting both higher treatment volumes and favorable reimbursement trends, solidifying its role as a key asset in the company’s portfolio.
Analyst Q&A Reveals Concerns on Receivables
During the analyst Q&A, several questions were raised about an unexpected $909,000 charge for accounts receivable, which management attributed to issues with insurance payers. Stokowiak explained, “This amount reflects reductions in the viability of certain receivables from insurance carriers, and we are actively working to improve our accounts receivable processes.” Analysts expressed concern about the recurring nature of such charges, prompting management to reassure them of ongoing improvements in billing and receivables management.
Frequently Asked Questions
Did American Shared Hospital Services beat earnings estimates in Q2 2026?
Yes, American Shared Hospital Services reported Q2 2026 revenue of approximately $8.4 million, exceeding the consensus estimate of $7.1 million.
What drove the revenue growth for American Shared Hospital Services in Q2 2026?
The revenue growth was primarily driven by a 40% increase in direct patient services revenue and a 22% rise in proton beam therapy revenue, reflecting higher patient volumes and improved operational performance.
How much cash did American Shared Hospital Services generate in the first half of 2026?
The company generated approximately $4.4 million in cash from operating activities during the first half of 2026, which helped increase its cash position to $6.8 million.
What was the impact of the accounts receivable charge on American Shared Hospital Services' earnings?
The charge of $909,000 for accounts receivable impacted the net loss reported during the quarter, but management indicated that they are making progress in improving their billing and collections processes to prevent future occurrences.
In summary, while American Shared Hospital Services faces challenges in its balance sheet management, the operational momentum and revenue growth indicate a positive trajectory for the company's future. The next quarter will provide further insight into how effectively the company can leverage its cash flow to strengthen its financial position and capitalize on growth opportunities.
This analysis is based on public earnings call materials and is not investment advice.
